IVF Outcomes: What May Help and Where Evidence Is Uncertain

Medically reviewed on 7 November 2026 - Dr. Senai Aksoy
A couple reviews printed documents with a physician at a wooden consultation table

Key Takeaways

Your age, how your ovaries responded, how the embryos developed, and your diagnosis guide an IVF plan. After a cycle that did not work, reviewing what happened and how safe the next plan is helps more than automatically adding more treatment. Many optional add-ons (extra tests or treatments) lack convincing evidence of more live births. Healthy habits support your general health but cannot guarantee success.

Key evidence: ASRM: fertility evaluation (2026) ESHRE: ovarian stimulation (2025 update) ESHRE: add-on recommendations (2023)

Where to Start

After an unsuccessful IVF cycle, it is natural to ask whether one more test or treatment would have changed the result. The place to start is a review of what happened, rather than a longer list of treatments. Sometimes that review points to a useful change. Sometimes it finds no clear cause that can be treated.

Here, “outcome” means the chance of a live birth (a baby born alive) as well as treatment safety. A positive pregnancy test, more eggs, or better-looking embryos are not the same as a live birth.

What Usually Matters Most

Age and Ovarian Reserve

When you use your own eggs, your age is an important predictor of IVF success. Two tests help estimate how the ovaries may respond to stimulation, the medicines that help several eggs grow. One is a blood test for anti-Müllerian hormone (AMH). The other is an ultrasound count of the small follicles in the ovaries (the antral follicle count). Neither measures egg quality directly, and neither can tell you for certain whether treatment will work. The fertility evaluation guidance from the American Society for Reproductive Medicine (ASRM) recommends reading these results alongside age, medical history, and previous response.

Embryo Development

Ask your fertility team to walk you through the sequence: how many eggs were collected, how many were mature, how many fertilised, and how many embryos kept developing. This can show where a change might be worth discussing. The reason a cycle failed can still remain unclear. For more on this, see the factors that influence IVF success.

The Uterus and Tubes

Whether a finding on a scan needs surgery depends on the likely benefit, and that varies with the finding and your medical history. Fibroids that distort the uterine cavity, polyps, and adhesions each need individual assessment. ASRM’s evaluation guidance supports choosing tests to fit the person rather than giving everyone the same invasive tests.

A hydrosalpinx is a different problem. The trouble lies in the fallopian tube, which is damaged and filled with fluid. When the affected tube opens into the uterus, ASRM’s tubal surgery guidance supports discussing whether to remove or block that tube before IVF.

Male Factor

The semen analysis and the male partner’s medical history belong in the assessment too. ICSI, in which a single sperm is injected into an egg, can address certain fertilisation problems. Surgical sperm retrieval is used in specific situations, such as some cases where no sperm are found in the ejaculate. Each one answers its own problem, so neither works as a general “boost” to success. The AUA/ASRM male infertility guideline sets out the indications for each.

Advanced sperm-selection methods need their own assessment. The add-on guidance from the European Society of Human Reproduction and Embryology (ESHRE) does not recommend routine PICSI (selection based on sperm binding to hyaluronic acid), IMSI (selection under high magnification), or magnetic sperm sorting. A laboratory improvement still has to be shown to mean more live births.

The Medical Steps Worth Reviewing

A useful plan explains what is changing and why. These are the points worth reviewing:

Dr. Aksoy’s Approach

When reviewing a previous IVF cycle, Dr. Senai Aksoy first looks at where difficulties arose: egg number, maturity, fertilisation, embryo development, or implantation. His point is practical: changing a drug brand without analysing why the protocol failed is not a new strategy. Even a well-reasoned plan cannot promise success.

Lifestyle: Helpful, but Not a Test of Willpower

General health and treatment safety matter. Ask for help to stop smoking, and discuss alcohol and any supplements with your team. If medication instructions are hard to follow, ask for them to be explained again. If an injection is missed or its timing is unclear, contact the clinic rather than changing the dose yourself.

Sleep, diet, and physical activity deserve attention without becoming another source of pressure. A failed cycle says nothing about how hard you tried.

Weight calls for a balanced conversation. ASRM’s obesity guidance notes that in women with obesity who ovulate, weight-loss interventions before treatment have not been shown to improve live-birth rates after IVF. Your general health and anaesthesia safety still matter, and so does the possible downside of delaying treatment. Any target weight or waiting period has to fit the individual patient.

How to Evaluate an Add-on

An add-on is an extra test or treatment offered alongside standard IVF. ESHRE’s 2023 recommendations advise against routine endometrial scratching (deliberately irritating the lining of the uterus).

The same recommendations advise against immune treatments such as Intralipid infusions (a fat emulsion) and intravenous immunoglobulin (IVIG, antibodies given into a vein) as fertility add-ons. Evidence of benefit is lacking, and there are safety concerns. This applies to their use to improve fertility outcomes, not to their use for a separate, diagnosed medical condition. If you already take an immune treatment for another condition, discuss it with the doctor who prescribed it and do not stop it yourself.

Before agreeing, ask:

You should be able to understand why something is recommended, without pressure to “try everything.” Read more about repeated IVF failure and the immune system.

At a Glance

DecisionWhat to askKeep in mind
Reviewing a previous cycleAt what stage did a difficulty arise, and could a change address it?Some failed cycles have no cause that can be found and corrected
Adjusting treatmentIs the aim better response, safer treatment, or more live births?These are different outcomes
Treating a uterine or tubal findingWhat is the diagnosis and the evidence for treating it?The need for surgery depends on the finding
Changing lifestyleWhat helps my health without needless delay?Good habits support health but cannot guarantee success
Adding an optional treatmentWhat is the evidence for this intervention in my situation?Each extra treatment needs evidence of its own

Frequently Asked Questions for Dr. Aksoy

After a failed or difficult IVF cycle, do optional add-ons usually increase the chance of a live birth?

After a failed IVF cycle, one of the questions I hear most is: “Doctor, what else can we add next time to improve the chance of success?” I understand that wish. But I explain that more procedures do not automatically mean a higher chance of pregnancy.

Many extras are offered — embryo glues, immune treatments, endometrial receptivity tests, growth hormone, and various laboratory technologies. Some may help in selected situations. For most of them, though, we do not have strong evidence that routine use raises live-birth rates. Some can even lead to unnecessary cost, side effects, and delays in treatment.

My approach is not to add new procedures automatically after a failed cycle. I first try to understand why the attempt may have failed. If we find a specific problem, we plan treatment for that problem. I do not think it is right to turn to unproven methods simply because the last cycle failed. What matters in IVF is not how many technologies we use, but whether they truly raise the chance of a healthy baby.

Evidence note: The ESHRE add-on recommendations do not recommend many of these extras for routine use, and the HFEA’s information for patients rates treatment add-ons on their evidence.

Do supplements such as CoQ10 or DHEA belong in an IVF plan?

After cycles with few eggs collected, or with poorer embryo development than expected, patients often ask whether they should take CoQ10 or DHEA. It is thought that CoQ10 may improve egg quality because it plays a role in cellular energy production. Some small studies have reported favourable findings for ovarian response and embryo development, but it has not yet been shown to raise live-birth rates reliably.

I am more cautious about DHEA. It has been used for years in women with low ovarian reserve, yet stronger research has not confirmed the hoped-for benefit. DHEA also has hormonal effects and possible side effects; it is not an ordinary vitamin. So I do not recommend DHEA routinely.

In suitable patients who want to use CoQ10, I may discuss it individually after explaining the uncertain benefit and the cost. Before either supplement, though, I look at the previous cycle in detail: how many follicles developed, how many mature eggs were collected, and how fertilisation and embryo development went. The most useful change for the next attempt may be adjusting the stimulation protocol or the timing of treatment, not a new supplement.

Evidence note: The ESHRE 2025 ovarian stimulation guideline does not recommend DHEA for women with a low or normal response to stimulation. The ESHRE add-on recommendations do not recommend antioxidant therapy in assisted reproduction; they do not name CoQ10 individually. For a fuller evidence review, see CoQ10, melatonin and NAC for oocyte quality.

After a failed IVF cycle, what should we review first before adding optional extras?

After a failed IVF cycle, my first step is not to order new tests. It is to review every stage of the previous treatment in detail. I start with the woman’s age, ovarian reserve, the medicines used, and how the ovaries responded. How many follicles developed? How many eggs were collected, and how many were mature? If we obtained fewer eggs than expected, why might that be?

I then look at the fertilisation rate, the sperm factor, and how the embryos developed on day 3 and day 5. If a transfer was done, I review embryo quality, the endometrium, progesterone support, and how the transfer was carried out technically.

When all of those stages look appropriate and only one embryo transfer has failed, it may often be more sensible to repeat the same well-planned approach than to launch a wide battery of investigations. If there was an unexpectedly poor ovarian response, fertilisation failure, a clear problem in embryo development, or a suspicious finding in the uterus, I direct the work-up to that point.

I do not automatically order immune tests, endometrial receptivity (ERA) testing, microbiome analysis, or sperm DNA fragmentation testing for every patient. Being able to run a test does not necessarily mean it is useful. The question that matters most to me is: will this result really change our plan, and do we have evidence that the change raises the chance of a live birth? If the answer is no, I prefer not to burden the patient with unnecessary tests.

FAQ: more questions about IVF outcomes

Is there one decisive step that improves IVF success?

No. The useful next step depends on the diagnosis and on what happened during treatment. Even after a careful review, there may be no clear explanation for a failed cycle.

Does lifestyle still matter during an IVF cycle?

Yes, for general health and treatment safety. It cannot guarantee pregnancy, and imperfect habits are not a reason to blame yourself for a failed cycle.

How should patients evaluate a suggested add-on?

Ask what the evidence shows for live births in patients like you, then ask about risks, cost, possible delay, and what happens if you decline it.

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.

Before getting in touch

Please note that certain services, such as sperm donation, egg donation, surrogacy and gender selection (without medical necessity), are not permitted under Turkish law.

We would like to inform you that our clinic strictly adheres to these regulations and does not offer any of these services.

Continue